HomePlatform & StrategiesPublications
ABL001, a bispecific antibody targeting VEGF and DLL4, with chemotherapy, synergistically inhibits tumor progression in xenograft models
2020
Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis
2016
첫페이지로이전 페이지로12
ABL Bio